Food and drug chief Gottlieb skirts health secretary talk, says most effective at FDA(Reuters) - U.S. Food and Drug Administration Commissioner Scott Gottlieb, considered a potential successor to recently departed Health and Human Services Secretary Tom Price, said on Tuesday he believed he could best serve the Trump administration in his current role.     “I feel like I want to continue to follow through on the policies we’ve put out and it’s where I think I can be most effective,” Gottlieb told Reuters in an interview in New York. He declined to say whether he had been approached about the job by the White House. “I’m not going to get into private discussions I might have had around that,” he said. Gottlieb is one of several potential candidates for the top job at HHS, a post vacated by Price last month following an uproar over his use of private jets for government business. Other names mentioned by health policy experts include Seema Verma, administrator of the Centers for Medicare & Medicaid Services (CMS) and Louisiana Governor Bobby Jindal. Gottlieb has won mostly positive reviews since taking over as FDA commissioner in May. He has introduced policies tackling some of the country’s biggest health challenges, including opioid and tobacco addiction and rising prescription drug prices.  The top post at the FDA has always been difficult to fill, Gottlieb noted, and there have been long stretches where the agency has operated under an acting commissioner. Gottlieb once served as senior adviser to FDA commissioner Mark McClellan, who left the agency in 2004 after just two years to run CMS, a move that Gottlieb said was detrimental to the agency. “It’s always challenging to move an FDA commissioner,” he said. “Continuity of leadership there is important.” In a wide-ranging interview, Gottlieb said the situation on the ground in Puerto Rico, where 10 percent of drugs prescribed in the United States are made, was “very bad” and that shortages of some drugs could emerge within as little as two to three weeks. He also said the agency is going to more clearly define regulations around cell therapies. The law currently states that if a cell is extracted from a patient’s body and more than minimally manipulated it is a drug subject to FDA regulation. “Historically the FDA hasn’t vigorously enforced around that line because it didn’t have the implementing guidelines to do that,” he said. At the same time, the agency plans novel measures to make it easier for small academic centers to apply for FDA product approval by pooling data generated from similar work. “If academicians working at different academic sites are doing a similar procedure with stem cells, if they are all following the same protocol, then they’re going to be able to pool their data to submit it for regulatory approval,” he said. politicsNews
food drug chief gottlieb skirts health secretary talk says effective fda reuters food drug administration commissioner scott gottlieb considered potential successor recently departed health human services secretary tom price said tuesday believed could best serve trump administration current role i feel like i want continue follow policies put i think i effective gottlieb told reuters interview new york he declined say whether approached job white house i going get private discussions i might around said gottlieb one several potential candidates top job hhs post vacated price last month following uproar use private jets government business other names mentioned health policy experts include seems versa administrator centers medical medical services cms louisiana governor bobby final gottlieb mostly positive reviews since taking fda commissioner may he introduced policies tackling country biggest health challenges including opioid tobacco addiction rising prescription drug prices the top post fda always difficult fill gottlieb noted long stretches agency operated acting commissioner gottlieb served senior adviser fda commissioner mark mcclellan left agency two years run cms move gottlieb said detrimental agency it always challenging move fda commissioner said continuity leadership in interview gottlieb said situation ground puerto rico percent drugs prescribed united states made bad shortages drugs could emerge within little two three weeks he also said agency going clearly define regulations around cell therapies the law currently states cell extracted patient body minimally manipulated drug subject fda regulation historically fda vigorously enforced around line implementing guidelines said at time agency plans novel measures make easier small academic centers apply fda product approval cooling data generated similar work if academician working different academic sites similar procedure stem cells following protocol going able pool data submit regulatory approval said politicsnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: Food and drug chief Gottlieb skirts health secretary talk, says most effective at FDA(Reuters) - U.S. Food and Drug Administration Commissioner Scott Gottlieb, considered a potential successor to recently departed Health and Human Services Secretary Tom Price, said on Tuesday he believed he could best serve the Trump administration in his current role.     “I feel like I want to continue to follow through on the policies we’ve put out and it’s where I think I can be most effective,” Gottlieb told Reuters in an interview in New York. He declined to say whether he had been approached about the job by the White House. “I’m not going to get into private discussions I might have had around that,” he said. Gottlieb is one of several potential candidates for the top job at HHS, a post vacated by Price last month following an uproar over his use of private jets for government business. Other names mentioned by health policy experts include Seema Verma, administrator of the Centers for Medicare & Medicaid Services (CMS) and Louisiana Governor Bobby Jindal. Gottlieb has won mostly positive reviews since taking over as FDA commissioner in May. He has introduced policies tackling some of the country’s biggest health challenges, including opioid and tobacco addiction and rising prescription drug prices.  The top post at the FDA has always been difficult to fill, Gottlieb noted, and there have been long stretches where the agency has operated under an acting commissioner. Gottlieb once served as senior adviser to FDA commissioner Mark McClellan, who left the agency in 2004 after just two years to run CMS, a move that Gottlieb said was detrimental to the agency. “It’s always challenging to move an FDA commissioner,” he said. “Continuity of leadership there is important.” In a wide-ranging interview, Gottlieb said the situation on the ground in Puerto Rico, where 10 percent of drugs prescribed in the United States are made, was “very bad” and that shortages of some drugs could emerge within as little as two to three weeks. He also said the agency is going to more clearly define regulations around cell therapies. The law currently states that if a cell is extracted from a patient’s body and more than minimally manipulated it is a drug subject to FDA regulation. “Historically the FDA hasn’t vigorously enforced around that line because it didn’t have the implementing guidelines to do that,” he said. At the same time, the agency plans novel measures to make it easier for small academic centers to apply for FDA product approval by pooling data generated from similar work. “If academicians working at different academic sites are doing a similar procedure with stem cells, if they are all following the same protocol, then they’re going to be able to pool their data to submit it for regulatory approval,” he said. politicsNews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: food drug chief gottlieb skirts health secretary talk says effective fda reuters food drug administration commissioner scott gottlieb considered potential successor recently departed health human services secretary tom price said tuesday believed could best serve trump administration current role i feel like i want continue follow policies put i think i effective gottlieb told reuters interview new york he declined say whether approached job white house i going get private discussions i might around said gottlieb one several potential candidates top job hhs post vacated price last month following uproar use private jets government business other names mentioned health policy experts include seems versa administrator centers medical medical services cms louisiana governor bobby final gottlieb mostly positive reviews since taking fda commissioner may he introduced policies tackling country biggest health challenges including opioid tobacco addiction rising prescription drug prices the top post fda always difficult fill gottlieb noted long stretches agency operated acting commissioner gottlieb served senior adviser fda commissioner mark mcclellan left agency two years run cms move gottlieb said detrimental agency it always challenging move fda commissioner said continuity leadership in interview gottlieb said situation ground puerto rico percent drugs prescribed united states made bad shortages drugs could emerge within little two three weeks he also said agency going clearly define regulations around cell therapies the law currently states cell extracted patient body minimally manipulated drug subject fda regulation historically fda vigorously enforced around line implementing guidelines said at time agency plans novel measures make easier small academic centers apply fda product approval cooling data generated similar work if academician working different academic sites similar procedure stem cells following protocol going able pool data submit regulatory approval said politicsnews